Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28718671 | 0.98 | RIPK1 (0.51) | RIPK1APPMRGPRX1HTR2CPDE4A | |
| SCHEMBL28333027 | 0.93 | RIPK1 (0.46) | RIPK1APPMRGPRX1HTR2CFAAH | |
| SCHEMBL28333102 | 0.92 | FAAH (0.48) | RIPK1APPMRGPRX1HTR2CFAAH | |
| SCHEMBL28333007 | 0.81 | HTR2A (0.48) | RIPK1HTR2CPDE4APDE4BPDE4C | |
| SCHEMBL22470688 | 0.80 | HTR2A (0.50) | RIPK1MRGPRX1HTR2CPDE4APDE4B | |
| SCHEMBL14798300 | 0.79 | MRGPRX1 (0.57) | RIPK1MRGPRX1PDE4APDE4BPDE4C | |
| SCHEMBL15053606 | 0.77 | MRGPRX1 (0.58) | RIPK1MRGPRX1PDE4APDE4BPDE4C | |
| SCHEMBL28151936 | 0.77 | CHRNB4 (0.44) | RIPK1 | |
| SCHEMBL22957615 | 0.76 | RIPK1 (0.62) | RIPK1HTR2CCARM1PRMT6ALDH1A1 | |
| SCHEMBL13105738 | 0.76 | RIPK1 (0.40) | RIPK1HTR2CPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566103-B | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113508109-B | Substituted heterocyclic amide compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-02-10 | — | — | CN | disclosed |
| CN-110520423-B | Aminotriazolopyridines as kinase inhibitors | 百时美施贵宝公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-113508109-A | Substituted heterocyclic amide compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-111566103-A | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | RIPK1 2195/4885APP 2129/4885MRGPRX1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.